AI Assisted Mechanistic and Translational Evaluation of Moringa oleifera in Breast Cancer: A Preclinical-to-Clinical Study

Abstract

The development of safer and multi-target therapy approaches is necessary because breast cancer continues to be one of the main causes of cancer-related mortality globally. The current study used an organized in-silico research framework and AI-assisted scientific prompting to assess the mechanistic and translational potential of Moringa oleifera in breast cancer. To construct a preclinical-to-clinical translational roadmap, the study combined pathway mapping, lead identification and optimization, in vitro and in vivo experimental design planning, clinical and pharmacovigilance framework creation, and market and intellectual property analysis. Important oncogenic pathways like PI3K/AKT/mTOR signaling, NF-κB inflammatory signaling, VEGF/HIF-1 mediated angiogenesis, STAT3 cytokine signaling, and oxidative stress–apoptosis pathways have been found to be multi-target modulated by key bioactive compounds like quercetin, moringin isothiocyanate, and niazimicin. While suggested experimental paradigms supported validation in triple-negative breast cancer cell lines like MDA-MB-231, lead optimization and ADMET analysis indicated acceptable drug-likeness and safety profiles for flavonoids and isothiocyanates. To assess safety and progression-free survival outcomes, translational planning also recommended a Phase II add-on clinical trial paradigm with pharmacovigilance monitoring. Standardized adjunct medicines based on Moringa oleifera have a great deal of promise for growth in oncology supportive care, according to market and intellectual property research. Overall, the study indicates that Moringa oleifera has translational potential and multi-target mechanistic relevance as an adjuvant therapy for breast cancer; nevertheless, the results are hypothesis-generating and need additional confirmation through in vitro, in vivo, and clinical investigations.